header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FIG-111102-13
Gore et al., 2011 - Rspo1/Wnt signaling promotes angiogenesis via Vegfc/Vegfr3. Development (Cambridge, England)   138(22):4875-4886 Full text @ Development
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Genes:
Fish:
Condition:
Knockdown Reagent:
Anatomical Terms:
Stage Range: Shield to Long-pec
PHENOTYPE:
Fish:
Knockdown Reagent:
Observed In:
Stage: Long-pec

Fig. 4

Upregulation of the Wnt/β-catenin pathway promotes angiogenesis. (A,B) Confocal images of trunk vessels in 48 hpf Rspo1 MO-injected wild-type (+/+) or heterozygous (apcmcr/+) embryo with ISV defects (A) or homozygous (apcmcr/apcmcr) mutant (B) with relatively normal ISV growth. (C) Quantitation of ISV phenotype of Rspo1 MO-injected wild type (+/+) or heterozygous (apcmcr/+) embryo and homozygous (apcmcr/apcmcr) mutant. (D,E) In situ hybridization of the trunks of 26 hpf wild-type zebrafish embryos treated from 16 hpf to 24 hpf with either carrier DMSO (D) or BIO (E), probed for cyclin D1. (F,G) In situ hybridization of the trunks of 6 hpf wild-type zebrafish embryos treated from 2.5 hpf to 6 hpf with either carrier DMSO (F) or BIO (G), probed for chordin. (H,I) Confocal images of hindbrain vessels in 48 hpf Rspo1 MO-injected embryos treated with carrier DMSO (H) or BIO (I). (J,K) Confocal images of trunk vessels in 40 hpf dtty135 mutant embryos treated with carrier DMSO (J) or BIO (K) from 16 hpf. (L) Quantitation of the intersegmental vessel (ISV) phenotypes of 40 hpf Tg(fli:EGFP)y1 dtty135 mutants treated from 16-40 hpf with either DMSO carrier or BIO. Bars show the percentages of ISV that have failed to sprout (blue), ISV that have grown only up to the horizontal myoseptum half-way up the trunk (red) and ISV that have grown all the way to the dorsal trunk to form the DLAV (yellow). The number of segments counted is shown above each bar. Scale bars: 50 μm in A,H,J.

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
ccnd1 y1Tg/y1Tg control Prim-5 trunk dorsal region ISH
y1Tg/y1Tg chemical treatment: pharmaceutical Prim-5 trunk dorsal region ISH
Prim-5 trunk ventral region ISH
chrd y1Tg/y1Tg control Shield margin posterior region ISH
y1Tg/y1Tg chemical treatment: pharmaceutical Shield margin ISH
EGFP apchu745/hu745; y1Tg/y1Tg + MO3-rspo1 standard conditions Long-pec axial vasculature IFL
Long-pec dorsal longitudinal anastomotic vessel IFL
Long-pec intersegmental vessel IFL
rspo1y135/y135; y1Tg/y1Tg control Prim-25 axial vasculature IFL
rspo1y135/y135; y1Tg/y1Tg chemical treatment: pharmaceutical Prim-25 axial vasculature IFL
Prim-25 dorsal longitudinal anastomotic vessel IFL
Prim-25 intersegmental vessel IFL
y1Tg/y1Tg + MO3-rspo1 chemical treatment: pharmaceutical Long-pec cranial blood vessel IFL
y1Tg/y1Tg + MO3-rspo1 standard conditions Long-pec axial vasculature IFL
Long-pec cranial blood vessel IFL
Long-pec intersegmental vessel IFL
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
apchu745/hu745; y1Tg/y1Tg + MO3-rspo1 standard conditions Long-pec intersegmental vessel present, normal
y1Tg/y1Tg + MO3-rspo1 standard conditions Long-pec anterior mesencephalic central artery absent, abnormal
Long-pec cerebellar central artery absent, abnormal
Long-pec intersegmental vessel decreased amount, abnormal
Long-pec middle mesencephalic central artery absent, abnormal
Long-pec posterior mesencephalic central artery absent, abnormal
Acknowledgments:
ZFIN wishes to thank the journal Development (Cambridge, England) for permission to reproduce figures from this article. Please note that this material may be protected by copyright. Full text @ Development